Index by author

June 01, 2005; Volume 72,Issue 6

A

  1. Aboussouan, Loutfi S.

    1. Respiratory disorders in neurologic diseases
      Loutfi S. Aboussouan, MD
      Cleveland Clinic Journal of Medicine June 2005, 72 (6) 511-520;

      Pulmonary complications often arise late in the course of neurologic diseases. Common principles apply in their management.

  2. Albertsen, Peter C.

    1. Prostate-specific antigen: How to advise patients as the screening debate continues
      Peter C. Albertsen, MD, MS
      Cleveland Clinic Journal of Medicine June 2005, 72 (6) 521-527;

      There is still no consensus on whether prostate-specific antigen measurement should be used as a screening test for prostate cancer, but patients have the right to be informed about its risks and possible benefits.

K

  1. Kunkel, Robert S.

    1. Migraine aura without headache: Benign, but a diagnosis of exclusion
      Robert S. Kunkel, MD
      Cleveland Clinic Journal of Medicine June 2005, 72 (6) 529-534;

      Migraine aura can occur alone, without being followed by a headache, but it should be diagnosed only when transient ischemic attack and seizure disorders have been excluded.

M

  1. Mandell, Brian F.

    1. In reply: Industry involvement in preparation of articles (March 2005)
      Brian F. Mandell, MD, PhD
      Cleveland Clinic Journal of Medicine June 2005, 72 (6) 463;
    2. IVUS: A better picture of coronary artery disease?
      Brian F. Mandell, MD, PhD
      Cleveland Clinic Journal of Medicine June 2005, 72 (6) 457;

      As an end point in a clinical trial, a change on intravascular ultrasonography is somewhere between a change in low-density lipoprotein cholesterol and a change in the mortality rate as evidence of efficacy of treatment.

  2. Murphy, Ross T.

    1. Genetics and cardiomyopathy: Where are we now?
      Genetics and cardiomyopathy: Where are we now?
      Ross T. Murphy, MD and Randall C. Starling, MD, MPH
      Cleveland Clinic Journal of Medicine June 2005, 72 (6) 465-483;

      Genetic discoveries have changed our understanding of the cardiomyopathies but are only beginning to change our clinical practice.

N

  1. Nissen, Steven E.

    1. Intravascular ultrasonography: Using imaging end points in coronary atherosclerosis trials
      Paul Schoenhagen, MD and Steven E. Nissen, MD
      Cleveland Clinic Journal of Medicine June 2005, 72 (6) 487-496;

      Intravascular ultrasonography can precisely measure plaque and is being used to test new drug therapies. Other imaging tests may also prove useful to identify people at risk for coronary artery disease and to monitor treatment.

S

  1. Schoenhagen, Paul

    1. Intravascular ultrasonography: Using imaging end points in coronary atherosclerosis trials
      Paul Schoenhagen, MD and Steven E. Nissen, MD
      Cleveland Clinic Journal of Medicine June 2005, 72 (6) 487-496;

      Intravascular ultrasonography can precisely measure plaque and is being used to test new drug therapies. Other imaging tests may also prove useful to identify people at risk for coronary artery disease and to monitor treatment.

  2. Starling, Randall C.

    1. Genetics and cardiomyopathy: Where are we now?
      Genetics and cardiomyopathy: Where are we now?
      Ross T. Murphy, MD and Randall C. Starling, MD, MPH
      Cleveland Clinic Journal of Medicine June 2005, 72 (6) 465-483;

      Genetic discoveries have changed our understanding of the cardiomyopathies but are only beginning to change our clinical practice.

T

  1. Tesar, George E.

    1. Treating depression in a mother of five: What to do when the first step fails
      George E. Tesar, MD
      Cleveland Clinic Journal of Medicine June 2005, 72 (6) 501-506;

      If depression does not respond to an antidepressant given in adequate doses for an adequate time, logical next steps include increasing the dose, adding a different medication, or adding nonpharmacologic therapy. Or one can reconsider the diagnosis.

Back to top

In this issue